Accepted Manuscript



Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway

S. Divakar, K. Saravanan, P. Karthikeyan, R. Elencheran, S. Kabilan, K.K. Balasubramanian, Rajlakshmi Devi, J. Kotoky, M. Ramanathan

PII: S0009-2797(16)30524-5

DOI: 10.1016/j.cbi.2017.07.023

Reference: CBI 8065

To appear in: *Chemico-Biological Interactions*

Received Date: 3 November 2016

Revised Date: 21 June 2017

Accepted Date: 26 July 2017

Please cite this article as: S. Divakar, K. Saravanan, P. Karthikeyan, R. Elencheran, S. Kabilan, K.K. Balasubramanian, R. Devi, J. Kotoky, M. Ramanathan, Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway, *Chemico-Biological Interactions* (2017), doi: 10.1016/j.cbi.2017.07.023.

Iminoenamine based novel androgen receptor antagonist exhibited anti-prostate cancer activity in androgen independent prostate cancer cells through inhibition of AKT pathway

S. Divakar[a], K. Saravanan[b], P. Karthikeyan[c], R. Elencheran[e], S. Kabilan[b], K. K. Balasubramanian[c, f], Rajlakshmi Devi[d], J. Kotoky[e], M. Ramanathan[a],*

[a]Department of Pharmacology, PSG College of Pharmacy, Coimbatore, Tamil Nadu, India.

[b]Department of Chemistry, Annamalai University, Chidambaram, Tamil Nadu, India.

[c]Shasun Research Centre, Kellakottaiyur, Chennai, Tamil Nadu, India.

[d]Department of Life Sciences, IASST, Guwahati, Assam, India.

[e]Department of Chemistry, IASST, Guwahati, Assam, India.

[f]Present affiliation, Department of Biotechnology, IIT Madras, Tamil Nadu, India

***Corresponding author**

Dr. M. Ramanathan, Professor,

Principal,

PSG College of Pharmacy,

Peelamedu,

Coimbatore - 04.

Email: muthiah.in@gmail.com

Phone: +918870009199

Abstract

Treatment by androgen receptor (AR) antagonists is one of the regimens for prostate cancer. The prolonged treatment with AR antagonist leads to the expression of point mutation in the ligand binding domain of the AR. This point mutation causes resistance to AR